Drugs / Ref-08-038
Ref-08-038
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03055143 | Sep 2008 → Nov 2009 | — | Sun Pharma Advanced Research Company Limited | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ref-08-038 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03055143 ↗ |
| Known as | Caelyx | “Caelyx® (Doxorubicin Hydrochloride) Liposome Injection, 2 mg/ml (50 mg/m2 Dose) of Schering-Plough, Belgium” NCT03055143 ↗ |
| Known as | Doxorubicin Hydrochloride | “Doxorubicin Hydrochloride) Liposome Injection, 2 mg/ml (50 mg/m2 Dose) of Schering-Plough, Belgium” NCT03055143 ↗ |
| Route | Intravenous | “2 mg/ml intravenous infusion” NCT03055143 ↗ |